Simultaneous subset tracing and miRNA profiling of tumor-derived exosomes via dual-surface-protein orthogonal barcoding.

Simultaneous subset tracing and miRNA profiling of tumor-derived exosomes via dual-surface-protein orthogonal barcoding.
复制标题

DOI:
10.1126/sciadv.adi1556
复制
发表时间:
2023-10-06
期刊:
影响因子:
13.6
通讯作者:
Yang, Chaoyong
Yang, Chaoyong
中科院分区:
综合性期刊1区
文献类型:
--
作者:
Lei, Yanmei;Fei, Xiaochen;Ding, Yue;Zhang, Jianhui;Zhang, Guihua;Dong, Liang;Song, Jia;Zhuo, Ying;Xue, Wei;Zhang, Peng;Yang, Chaoyong

文献摘要

参考文献

相似文献

基于miRNA的液体活检的临床潜力在很大程度上受到血浆来源的异质性和繁琐的检测过程的限制。在这里,我们发展了一种精确和稳健的一锅法,称为双表面蛋白引导的肿瘤来源外体的正交识别和原位微RNAs分析(SORTER),以检测肿瘤来源的外体miRNAs,并提高前列腺癌(PCa)的诊断准确性。该分类器使用针对外体标记CD63和肿瘤标记EpCAM的两个变构适配子来创建正交标记条码,实现对肿瘤特异性外体亚型的选择性分选。此外,肿瘤外体上的标记条形码启动了与脂质体探针的靶向膜融合,以进口miRNA检测试剂,从而实现了对肿瘤外体miRNAs的原位灵敏图谱。根据6个miRNAs的特征,Sorter鉴别前列腺癌和良性前列腺增生症的准确率为100%。值得注意的是,在转移性和非转移性前列腺癌的分类中,诊断准确率达到90.6%。我们预计,该分选器将促进基于miRNA的液体活检的临床适应性。该一锅分选器分析了0.2μL血浆中肿瘤来源的外体miRNAs,从而实现了前列腺癌的早期诊断。
The clinical potential of miRNA-based liquid biopsy has been largely limited by the heterogeneous sources in plasma and tedious assay processes. Here, we develop a precise and robust one-pot assay called dual-surface-protein-guided orthogonal recognition of tumor-derived exosomes and in situ profiling of microRNAs (SORTER) to detect tumor-derived exosomal miRNAs and enhance the diagnostic accuracy of prostate cancer (PCa). The SORTER uses two allosteric aptamers against exosomal marker CD63 and tumor marker EpCAM to create an orthogonal labeling barcode and achieve selective sorting of tumor-specific exosome subtypes. Furthermore, the labeled barcode on tumor-derived exosomes initiated targeted membrane fusion with liposome probes to import miRNA detection reagents, enabling in situ sensitive profiling of tumor-derived exosomal miRNAs. With a signature of six miRNAs, SORTER differentiated PCa and benign prostatic hyperplasia with an accuracy of 100%. Notably, the diagnostic accuracy reached 90.6% in the classification of metastatic and nonmetastatic PCa. We envision that the SORTER will promote the clinical adaptability of miRNA-based liquid biopsy. The one-pot SORTER assay profiled tumor-derived exosomal miRNAs in 0.2 μl plasma, allowing for early diagnosis of prostate cancer.
DOI: 10.1126/science.aau6977
发表时间: 2020-02-07
期刊: Science (New York, N.Y.)
影响因子: --
作者:
Kalluri R;LeBleu VS
通讯作者: LeBleu VS
DOI: 10.1002/smll.202002800
发表时间: 2020-09-02
期刊: SMALL
影响因子: 13.3
作者:
Chen, Xiaohui;Jia, Mei;Luo, Yang
通讯作者: Luo, Yang
DOI: 10.1038/s41592-020-01034-x
发表时间: 2021-01-11
期刊: NATURE METHODS
影响因子: 48
作者:
Chen, Yuchao;Zhu, Qingfu;Liu, Fei
通讯作者: Liu, Fei
使用模拟病毒融合囊泡快速检测外泌体 MicroRNA
DOI: 10.1002/anie.201901997
发表时间: 2019-06-24
影响因子: 16.6
作者:
Gao, Xihui;Li, Sha;Zhang, Chuan
通讯作者: Zhang, Chuan
DOI: 10.1002/anie.202207037
发表时间: 2022-07-11
影响因子: 16.6
作者:
Deng, Jinqi;Zhao, Shuai;Sun, Jiashu
通讯作者: Sun, Jiashu